Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers
NCT02172235 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2014-06-24
Summary
The objective was to investigate the effect of different doses of BI 10773 on the bioavailability of pioglitazone after multiple oral doses of both drugs
Conditions
- Healthy
Interventions
- DRUG
-
Pioglitazone
- DRUG
-
Pioglitazone - low dose
- DRUG
-
BI 10773 - low dose
- DRUG
-
BI 10773 - medium dose
- DRUG
-
BI 10773 - high dose
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-04-30
- Primary Completion
- 2010-07-31
More Related Trials
-
Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers
NCT02172261 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers
NCT01242176 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers
NCT02172209 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers
NCT02259972 ·Status: COMPLETED ·Phase: PHASE1
-
To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706
NCT01763333 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects
NCT02182323 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects
NCT02266485 ·Status: COMPLETED ·Phase: PHASE1
-
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
NCT01189201 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers
NCT02782624 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469
NCT01971502 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS
NCT02180503 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers
NCT01301742 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers
NCT02222168 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects
NCT02183493 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.
NCT01978652 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects
NCT02229773 ·Status: COMPLETED ·Phase: PHASE1
-
Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects
NCT02182271 ·Status: TERMINATED ·Phase: PHASE1
-
A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers
NCT05690932 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects
NCT02172170 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
NCT02068690 ·Status: COMPLETED ·Phase: PHASE1
-
Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers
NCT02212938 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200
NCT05160389 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers
NCT02173652 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food
NCT01286571 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
NCT02044406 ·Status: COMPLETED ·Phase: PHASE1